<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[investment and renaissance capital Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/investment+and+renaissance+capital.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to investment and renaissance capital]]></description>
	<s:counts start="0" returned="3" found="3" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Jobs roundup: Ex-communist states show pulling power.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5555/is_200310/ai_n21929416]]></link>
		<description><![CDATA[Byline: Sarah Butcher    The lure of the former Soviet bloc was in evidence in the job  market last week. A senior Merrill Lynch banker left London for a rival  bank in Moscow, tempted by the booming Russian mergers and acquisitions  sector and generous pay.Chris...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 06 Oct 2003 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/bank.html"><![CDATA[bank]]></category>
		<category domain="http://resources.bnet.com/topic/credit+suisse+group+ag.html"><![CDATA[Credit Suisse Group AG]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[job]]></category>
		<category domain="http://resources.bnet.com/topic/london.html"><![CDATA[London]]></category>
		<category domain="http://resources.bnet.com/topic/m%2526a.html"><![CDATA[M&A]]></category>
		<category domain="http://resources.bnet.com/topic/merrill+lynch+%2526+co.+inc..html"><![CDATA[Merrill Lynch & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/moscow.html"><![CDATA[Moscow]]></category>
		<category domain="http://resources.bnet.com/topic/renaissance+capital.html"><![CDATA[Renaissance Capital]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MER</category>
		<category domain="tickers">MER</category>
	</item>
	<item>
		<title><![CDATA[Weekly NAV to be Reported]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1999_Jan_27/ai_53653489]]></link>
		<description><![CDATA[DALLAS--BUSINESS WIRE--Jan. 27, 1999--Renaissance Capital Growth & Income Fund III, Inc. (Nasdaq: RENN) announced today that, beginning 1 February 1999, the Net Asset Value NAV of its investments will be estimated on a weekly basis and reported to Bloomberg Financial Markets every Monday.  These estimates will be calculated consistent...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 27 Jan 1999 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/business+wire.html"><![CDATA[Business Wire]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/renaissance+capital.html"><![CDATA[Renaissance Capital]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Biopharmaceutics, Inc. Closes Its Generic Drug Manufacturing Subsidiary and Announces Equity Capital Injection]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1999_Jan_15/ai_53579639]]></link>
		<description><![CDATA[BELLPORT, N.Y.--BUSINESS WIRE--Jan. 15, 1999--Biopharmaceutics, Inc. (OTCBB:BOPM) announced today, that it has ceased all production at its generic and contract pharmaceuticals division.  Jonathan Rosen, Acting President and CEO of Biopharmaceutics, Inc., said; "Our drug manufacturing division does not fit with our overall strategy for growth. This closure will allow...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 15 Jan 1999 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/board.html"><![CDATA[board]]></category>
		<category domain="http://resources.bnet.com/topic/business+wire.html"><![CDATA[Business Wire]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/equity.html"><![CDATA[equity]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/renaissance+capital.html"><![CDATA[Renaissance Capital]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
